| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4026004 | Ophthalmology | 2015 | 8 Pages |
Abstract
Visual function outcomes were similar across all NEI VFQ-25 subscales over 52 weeks for intravitreal aflibercept 2q8 and ranibizumab 0.5q4, with clinically meaningful improvement recorded in 6 of 12 subscales.
Keywords
AMDQOLETDRSNEI VFQ-25VRQoLVEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD2q8Quality of lifeVisual acuityage-related macular degenerationVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)25-item National Eye Institute Visual Function QuestionnaireViewVision-related quality of life
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Mitsuko MD, Kyoko MD, Kim U. PhD, Christiane MS, Oliver MD, Kenji PhD, Edward C.Y. PharmD, MBA, Jeffrey MD, Peter MD, Victor MD, Jean-Francois MD,